Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance

BACKGROUND: The epidermal growth factor receptor (EGFR) inhibitors represent the first-line therapy regimen for non-small cell lung cancer (NSCLC). Most of these inhibitors target the ATP-site to stop the aggressive development of NSCLC. Stabilization of the ATP-binding on EGFR is difficult due to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Maity, Swastika, Pai, K. Sreedhara Ranganath, Nayak, Yogendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381467/
https://www.ncbi.nlm.nih.gov/pubmed/32666476
http://dx.doi.org/10.1007/s43440-020-00131-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381467/
https://www.ncbi.nlm.nih.gov/pubmed/32666476
http://dx.doi.org/10.1007/s43440-020-00131-0

Ejemplares similares